Protalix BioTherapeutics Q2 2024 GAAP EPS $(0.03) Misses $0.02 Estimate, Sales $13.474M Beat $12.500M Estimate
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics reported its Q2 2024 financial results with a GAAP EPS of $(0.03), missing the estimate of $0.02. However, the company reported sales of $13.474 million, beating the estimate of $12.500 million.
August 14, 2024 | 10:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Protalix BioTherapeutics reported mixed Q2 2024 results with a GAAP EPS of $(0.03), missing the $0.02 estimate, but sales of $13.474 million beat the $12.500 million estimate.
The mixed earnings report for Protalix BioTherapeutics, with an EPS miss but a sales beat, is likely to result in a neutral short-term impact on the stock price. Investors may weigh the negative EPS against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100